OncoMatch/Clinical Trials/NCT06128148

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Is NCT06128148 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for protein kinase inhibitors.

Phase 1RecruitingGuangzhou JOYO Pharma Co., LtdNCT06128148Data as of May 2026

Treatment: JYP0322 50 mg qd · JYP0322 100 mg qd · JYP0322 200 mg qd · JYP0322 100 mg bid · JYP0322 150 mg bid · JYP0322 200 mg bid · JYP0322 150mg tid — An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: ROS1 fusion

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify